Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years

JAMA Ophthalmology Author Interviews
09/01/2012 7 min
Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years

Listen "Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years"

Descargar episodio Ver en sitio original

Episode Synopsis

Interview with Samuel G. Jacobson, MD, PhD, author of Gene Therapy for Leber Congenital Amaurosis Caused by RPE65 Mutations: Safety and Efficacy in 15 Children and Adults Followed Up to 3 Years

More episodes of the podcast JAMA Ophthalmology Author Interviews

Diabetes in the Donor and Descemet Membrane Endothelial Keratoplasty Success at 1 Year 17/10/2025
Smooth Pursuit Velocity After a Season of Repetitive Head Impacts in American Football Players 18/09/2025
Mammalian Target Rapamycin Inhibition for Proliferative Vitreoretinopathy 07/08/2025
Steroids and Cross-Linking for Ulcer Treatment 24/07/2025
From the JAMA Network: GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension 17/07/2025
Gender Differences in Case Volume Among Ophthalmology Resident Graduates, 2014-2023 01/05/2025
Continuous Ranibizumab via Port Delivery System vs Monthly Ranibizumab 06/03/2025
Shedding LiGHT on Selective Laser Trabeculoplasty 20/02/2025
Ophthalmic Complications Associated With Semaglutide and Tirzepatide 30/01/2025
Ultra-Widefield Optical Coherence Tomography Beyond the Ora Serrata in ROP 26/12/2024
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA